1. Brain signalling systems: A target for treating type I diabetes mellitus
- Author
-
R. Ramakrishnan
- Subjects
0301 basic medicine ,Blood Glucose ,Indoles ,medicine.medical_treatment ,S100 Calcium Binding Protein beta Subunit ,Pharmacology ,Protein Serine-Threonine Kinases ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Insulin resistance ,Ca2+/calmodulin-dependent protein kinase ,Diabetes Mellitus ,Medicine ,Animals ,Humans ,Insulin ,Phosphorylation ,Receptor ,Serotonin Plasma Membrane Transport Proteins ,Kinase ,business.industry ,General Neuroscience ,Brain ,medicine.disease ,Rats ,Disease Models, Animal ,030104 developmental biology ,Diabetes Mellitus, Type 1 ,Indolamines ,chemistry ,Hyperglycemia ,Insulin Resistance ,business ,Tyrosine kinase ,Protein Kinases ,030217 neurology & neurosurgery ,Signal Transduction - Abstract
From early to later stages of Type I Diabetes Mellitus (TIDM), signalling molecules including brain indolamines and protein kinases are altered significantly, and that has been implicated in the Metabolic Disorders (MD) as well as impairment of retinal, renal, neuronal and cardiovascular systems. Considerable attention has been focused to the effects of diabetes on these signalling systems. However, the exact pathophysiological mechanisms of these signals are not completely understood in TIDM, but it is likely that hyperglycemia, acidosis, and insulin resistance play significant roles. Insulin maintains normal glycemic levels and it acts by binding to its receptor, so that it activates the receptor's tyrosine kinase activity, resulting in phosphorylation of several substrates. Those substrates provide binding/interaction sites for signalling molecules, including serine/threonine kinases and indolamines. For more than two decades, our research has been focused on the mechanisms of protein kinases, CaM Kinase and Serotonin transporter mediated alterations of indolamines in TIDM. In this review, we have also discussed how discrete areas of brain respond to insulin or some of the pharmacological agents that triggers or restores these signalling molecules, and it may be useful for the treatment of specific region wise changes/disorders of diabetic brain.
- Published
- 2019